Cellective Raises $5M Bridge To $25M Series B

 

CELLective Dx develops cancer diagnostic to analyze cancer form CTC  form  patients’ blood  through bio chip diagnostic  tools and using  the dynamics of micro fluidic technology.  Cellective Dx takes advantage of rare circulating tumour cells in cancer patients by  bio chip technology in ability  to isolate cells  for cancer diagnostics.

Viable tumour-derived epithelial cells (circulating tumour cells or CTCs) have been identified in peripheral blood from cancer patients and are probably the origin of intractable metastatic disease. Although extremely rare, CTCs represent a potential alternative to invasive biopsies as a source of tumour tissue for the detection, characterization and monitoring of non-haematologic cancers. The ability to identify, isolate, propagate and molecularly characterize CTC subpopulations could further the discovery of cancer stem cell biomarkers and expand the understanding of the biology of metastasis

development of a unique microfluidic platform (the ‘CTC-chip’) capable of efficient and selective separation of viable CTCs from peripheral whole blood samples, mediated by the interaction of target CTCs with antibody (EpCAM)-coated microposts.

The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer.

The CTC-chip provides a new and effective tool for accurate identification and measurement of CTCs in patients with cancer. It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer.

Cellective  raised the bridge  financing from  previous investors Mohr Davidow Ventures and Northgate Capital. Cellective Dx  was  formerly named CellPoint Diagnostics and has  previously raised  $19M in capital total, after having closed an $11.2 M first round in funding